학술논문
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Document Type
Article
Author
Rudin, Charles M; Pietanza, M Catherine; Bauer, Todd M; Ready, Neal; Morgensztern, Daniel; Glisson, Bonnie S; Byers, Lauren A; Johnson, Melissa L; Burris, Howard A, III; Robert, Francisco; Han, Tae H; Bheddah, Sheila; Theiss, Noah; Watson, Sky; Mathur, Deepan; Vennapusa, Bharathi; Zayed, Hany; Lally, Satwant; Strickland, Donald K; Govindan, Ramaswamy; Dylla, Scott J; Peng, Stanford L; Spigel, David R
Source
In The Lancet Oncology January 2017 18(1):42-51
Subject
Language
ISSN
1470-2045